On December 7th the Mexican regulatory agency COFEPRIS approved the marketing authorizations for the Pfizer and Moderna COVID-19 Vaccines. The recent approval may appear odd, but the reason is that these two COVID vaccines and other products necessary to overcome all aspects of the pandemic, were approved by COFEPRIS on emergency basis.
Due to the legal grounds of emergency approvals and the Mexican health policy to maintain distribution and application of COVID vaccines in the public sector exclusively and a strict vaccination campaign established by the federal government, it was until recently that COFEPRIS approved the marketing authorizations for the COVID vaccines by Pfizer and Moderna. Other vaccine approvals are expected soon.
The impact of the recent approvals will be reflected in the importation, distribution, and commercialization of these COVID vaccines in the private sector, something that was litigated in the past before Mexican Courts to overcome the above-mentioned restrictions. OLIVARES was fully alert about the corresponding litigation and now we are closely following the implementation of the approvals in the private sector.
FOR FURTHER INFORMATION ON THE CONTENT OF THIS NEWSLETTER, PLEASE CONTACT:
Alejandro Luna F.
Alejandro Luna joined OLIVARES in 1996 and being made partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices. He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.
Armando Arenas joined OLIVARES in 2000 and became a partner in January 2017. He has experience working on a range of IP matters, including consulting and litigation on trademark, patent, unfair competition, trade dress protection, and misleading advertising cases before the Mexican Institute of Industrial Property (IMPI), Federal Court of Tax and Administrative Affairs (FCTA), Federal Circuit Courts (FCC) and the Supreme Court of Justice (SCJ) Regulatory Affairs and Public Acquisitions.